We conducted genome sequencing to search for rare variation contributing to early onset Alzheimer's 21 disease (EOAD) and frontotemporal dementia (FTD). Discovery analysis was conducted on 493 cases and 22 671 controls of European ancestry. Burden testing for rare variation associated with disease was 23 conducted using filters based on variant rarity (less than 1 in 10,000 or private), computational prediction of 24 deleteriousness (CADD 10 or 15 thresholds), and molecular function (protein loss-of-function only, coding 25 alteration only, or coding plus non-coding variants in experimentally predicted regulatory regions). 26
INTRODUCTION 40
Neurodegeneration with a clinical onset prior to the age of 65 can be devastating for patients, their 41 families, and caregivers, imposing financial burden and hardship during a period of life when individuals are 42 often most productive 1 . Early-onset neurodegenerative diseases such as early-onset Alzheimer's disease 43 (EOAD) and frontotemporal dementia (FTD) are typically thought of as disease forms with highly penetrant 44 genetic contributions, and indeed both can result from Mendelian pathogenic mutations (with Mendelian 45 causes more common in FTD) 2 . However, these diseases exhibit a high degree of heritability that remains 46 unexplained by currently known genetic contributors 3; 4 . This suggests that additional genetic factors likely 47 contribute to disease but have not yet been identified. Despite attempts at genome-wide association study 48 (GWAS) of relatively sizeable cohorts, only modest association signals have been identified for FTD 5 and 49 one form of EOAD, posterior cortical atrophy 6 . In contrast, sequencing studies have been successful at 50 identifying more moderately to highly penetrant contributions to disease by examining rare variation. 51
Successes in Alzheimer's disease (AD) include ABCA7, SORL1, and TREM2 (reviewed in 7 ). Similar 52 successes for the amyotrophic lateral sclerosis (ALS)-FTD spectrum include TBK1 8 , MFSD8 9 , DPP6, 53 UNC13A, and HLA-DQA2 10 . Despite these successes, the rarity of these diseases along with the high cost 54
of sequencing studies has resulted in limited sample sizes of patient cohorts. Furthermore, prior studies 55 have focused on coding regions of the genome, leaving non-coding regions largely unexplored for their 56 contribution to disease risk. 57
GenoSkyline-Plus 38 as potential regulatory regions. GenoSkyline-Plus incorporates chromatin marks, DNA 121 accessibility, RNA-seq, and DNA methylation to predict function. All tracks derived from direct human 122 tissue sources were included (sources propagated in culture were excluded), with a total of 50 of 66 tissue 123 and cell types described in Table S2 of 38 used for annotation (see Supplemental Table 1 for included 124 epigenome tracks in the union). 125 regions as well. Variants upstream or downstream (within 5kb, the SnpEff default) were also assigned to 149 their adjacent genes. The number of qualifying individuals was the final count unit, where one or more 150 qualifying variants in a gene for a given individual resulted in that individual having a qualifying count for 151 that gene (i.e., if an individual had two qualifying variants, they would still only be counted once to account 152 for the possibility of a recessive model of inheritance or negligibility of the 2 nd variant if on the same allele). 153 Individuals with more than three qualifying variants in a gene were not counted as qualifying because an 154 excess of rare and predicted damaging variants in a single gene may be indicative of a sequencing or 155 variant-calling error. 156 characteristics, cognitive testing, and genetic sequencing. Participants were diagnosed as either normal 177 controls (CN), mild cognitive impairment (MCI), or Alzheimer's disease (AD) (note that some participants 178 progressed from MCI to AD while being followed, with the last assessment used for case designation in the 179 replication analysis, while they may be designated as beginning at the MCI stage in the following analysis). 180
For clinical rate of progression analysis we used the Clinical Dementia Scale Sum of Boxes Score 181 (CDRSB) 43 , a broad measure of clinical progression and impairment well-validated in multiple studies 44; 45 . 182 We used linear mixed-effects modeling to test whether variation in TET2 predicts longitudinal 183 clinical progression using R version 3.5.2. We covaried for baseline age, sex, education, and CDRSB score 184 as well as APOE !4 dose. The model was implemented as follows: ∆ CDRSB = β0 + β1Agebaseline × ∆t + 185 β2Sexfemale × ∆t + β3Educationbaseline × ∆t + β4CDRSBbaseline × ∆t + β5APOE 4dose × ∆t + β6TET2carrier status × ∆t + 186 European ancestry: 493 cases (228 EOAD and 265 FTD) and 671 controls. All demographic available 201 information for each sample (case category, primary clinical diagnosis, sex, age at enrollment, APOE ε4 202 status, self-reported race/ethnicity, and principal components 1-4 and 5 ADMIXTURE coefficients) is 203 available in Supplemental Table 3 . The majority of cases were clinically diagnosed and did not have autopsy material available for neuropathological sub-grouping at the time of analysis. Primary clinical 205 diagnoses included as AD were logopenic variant primary progressive aphasia (29), posterior cortical 206 atrophy (26), frontal AD (17), language AD (17), vascular AD (8), AD + dementia with Lewy bodies (DLB) 207 (5), and AD not otherwise specified (126) . Primary clinical diagnoses included as FTD were behavioral 208 variant FTD (83), corticobasal syndrome (65), nonfluent variant primary progressive aphasia (43), FTD + 209 ALS (20) , primary supranuclear palsy (17), semantic variant primary progressive aphasia (17), argyrophilic 210 grain disease (5), and FTD not otherwise specified (15). The expected enrichment in APOE ε4 was 211 observed in AD cases (58% with at least one APOE ε4 allele versus 28% in controls, *p=1.8x10 -16 by 212
Fisher's exact test), but not in FTD (28% in FTD and controls, p=0.87) . 213
We compared EOAD vs. control, FTD vs. control, or a combined analysis of EOAD and FTD vs. 214 control across all variant filtering conditions (see Methods). In the discovery analysis of combined burden 215 across EOAD and FTD vs. control, with variants absent from population databases and with a CADD score 216 > 10 (including non-coding variants in GenoSkyline-Plus regions), one gene-disease association passed 217 the multiple comparison significance threshold: TET2 (SKAT uncorrected p=6.5x10 -8 , corrected p=0.0037; 218 Table 1 , model corrects for number of APOE ε4 alleles, sex, principal components 1-4, and 5 219 ADMIXTURE ancestral proportions). Note that, while we applied a multiple correction cutoff of 57,354 220 based on three main clusters of correlated filter conditions (Supplemental Figure 2) , the p value for TET2 221 would also pass a strict Bonferroni correction for 516,186 implicit tests (19,118 genes, 27 filter conditions) if 222 we conservatively did not consider the correlated nature of the different filter sets (Bonferroni p=0.033). 223
Statistical tests separately comparing EOAD vs. control and FTD vs. control did not pass the same degree 224 of multiple testing correction but results for those comparisons are provided in Supplemental Tables 4 225 (EOAD) and 5 (FTD) and demonstrate that the nominal enrichment level in TET2 is similar in both EOAD 226 and FTD. No other gene reached even nominal significance (p < 1x10 -5 ) in any filter condition, so TET2 227 was the only gene considered for replication analysis. However, in the interest of making data from this 228 study highly available, counts and p values for all genes assessed are provided in Supplemental Table 6 . 229
All qualifying variants in cases for TET2 were both Sanger validated and visually evaluated in the 230 Integrative Genomics Viewer (IGV). Two variants failed Sanger validation (adjacent erroneous indel calls in Table 7 where all qualifying variants in TET2 are listed. In addition, two cases had adjacent variant calls 233 that were found to make up one variant. These were also corrected in all statistical analyses and tables. 234
The single control with a qualifying TET2 variant did not have material available for Sanger sequencing but 235 appeared valid in IGV (a single nucleotide variant with 8 alternate allele reads among 18 total reads). 236
Next, we assessed potential confounding due to stratification by a QQ plot of the p-value 237 distribution for the filter set that produced the top result and observed no genomic inflation consistent with a 238 well-matched case-control dataset (l = 0.95, Figure 1) . 239
To help inform the types of sequencing datasets to target for replication, we assessed the variant 240 type (coding or non-coding) and associated disease for all qualifying TET2 variants in the discovery set. 241
Qualifying variants were observed in 11 EOAD cases, eight FTD cases, and one control. Of the 11 EOAD 242 cases, one had depressive symptoms, one had language symptoms and possible corticobasal syndrome, 243 one had logopenic variant primary progressive aphasia, and one had a previous diagnosis of behavioral 244 variant FTD revised to frontal AD (seven had no additional noted phenotypes). Of the eight FTD cases, 245 three had corticobasal syndrome (one of whom had AD symptoms and possible posterior cortical atrophy), 246 one had FTD + ALS, and four had behavioral variant FTD (one with AD symptoms and one with seizures). 247
Nine cases in total harbored coding variants, seven of which were canonical loss-of-function variants (four 248 EOAD and three FTD). Because non-coding variants make up a large portion of the signal, we assessed 249 coding and non-coding variants separately. We observed a similar level of enrichment for both coding and 250 non-coding variants in EOAD and FTD cases when these types of variants were considered independently 251 of one another (Figure 2A) . Furthermore, the non-coding variants were prevalent in regions predicted to 252 have regulatory function ( Figure 2B) . Combined with the high number of canonical loss-of-function 253 variants, these data support a model whereby TET2 haploinsufficiency, resulting from either canonical loss-254 of-function variation or expression-altering non-coding variation, may contribute risk to neurodegenerative 255 disease. 256
To replicate this finding, we used six additional cohorts (five independent, one internal) with 257 available sequencing data from patients diagnosed with a neurodegenerative disorder and healthy controls. 258
Based on the variants discovered in TET2, we attempted to replicate the association between aggregate 259 rare variant burden in TET2 and disease risk using two arms: the same conditions used in discovery applied to other genome sequencing datasets as a primary measure, and canonical loss-of-function only 261 analysis as a secondary measure to allow for incorporation of exome sequencing datasets. We assessed 262 three cohorts with genome sequencing data for replication using the same conditions applied in the 263 discovery set: ADSP (the Alzheimer's Disease Sequencing Project) (2,208 late-onset AD (LOAD) cases 264 and 2,208 controls), the Accelerating Medicines Partnership -Alzheimer's Disease (AMP-AD) cohort (749 265 LOAD, 184 FTD, and 446 controls), and the non-European ancestry individuals from our cohort not 266 assessed in the discovery set (66 EOAD, 79 FTD, and 157 controls). Assessment of these three cohorts 267 revealed replication of the signal for TET2 overall for early-and late-onset AD and FTD combined vs. 268 control (p=0.0071; Table 1 ). Although the statistics for separate analyses of EOAD vs. control and FTD vs. 269 control did not meet significance criteria, secondary analysis of those subgroups revealed similar levels of 270 enrichment within each distinct condition (Supplemental Finally, we assessed predicted loss-of-function variants alone in all aforementioned cohorts (UCSF 277 European discovery set, UCSF non-European replication set, ADSP, AMP-AD, Project MinE) along with 278 exome sequencing data from a second ALS dataset 8 and additional exome samples from ADSP 48 for a 279 total of seven sample sets. We observed a robust signal for association between predicted canonical loss-280 of-function variants and disease across multiple disease cohorts ( Table 2) . Specifically, three of the four 281 largest independent replication cohorts (ADSP genomes (LOAD), ADSP exomes (LOAD), and HA-Duke-282
Stanford ALS exomes) all exhibit independent nominal replication (p<0.05). Meta-analysis of all canonical 283 loss-of-function variants from all available cohorts (across EOAD, LOAD, FTD, and ALS) yields a p-value 284 below commonly used exome-wide significance cutoffs (p=2.5x10 -7 ; Table 2), and subgroup analyses of 285 both AD and FTD-ALS vs. controls were each nominally significant (p<0.05) and suggest similar degrees 286 of enrichment.
To assess potential clinical implications of rare variation in TET2, we queried the Alzheimer's 288 Disease Neuroimaging Initiative (ADNI) dataset [40] [41] [42] , which includes clinical rate of progression data. We 289 used linear mixed-effects modeling to test whether qualifying rare variation (based on the discovery 290 condition that passed multiple corrections testing) in TET2 predicts longitudinal clinical progression. We 291 covaried for baseline age, sex, education, and CDRSB score as well as APOE !4 dose. A total of 786 292 ADNI participants had TET2 genotypes available for analysis. There was no significant difference in the 293 distribution of TET2 rare variant carriers by sex, APOE !4 dose, education, or baseline CDRSB score 294 (Supplemental Table 8 ). There was a significant difference between TET2 rare variant carriers and non-295 carriers by baseline age (Supplemental Table 8 ) but recall that baseline age is corrected for as a 296 covariate along with sex, education, APOE !4 dose, and baseline CDRSB score. Using linear mixed effects 297 regression, we found a significant relationship between carrying any TET2 rare variant and clinical 298 progression as measured by change in CDRSB score (β ± SE = 0.14 ± 0.06; *p=0.03) (Figure 3) . A similar 299
finding was observed when our analyses were limited to TET2 loss-of-function variant carriers (β ± SE = 300 0.17 ± 0.09; *p=0.04) (Supplemental Figure 3 ) (although we corrected for covariates for rigor, no 301 covariates were significantly associated with TET2 loss-of-function carrier status (Supplemental Table 9 )). 302
We also explored whether rare variation in TET2 predicted changes in CDRSB and cognition (measured by 303
Mini Mental State Exam (MMSE) score changes 49 ) in MCI and control when analyzed separately. To 304 maximize sample size, we limited this analysis to all TET2 variant carriers without further subdivision to 305 loss-of-function variant carriers. When constraining the analysis to MCI, TET2 rare variant carriers (n=8) 306 demonstrated a greater CDRSB change over time compared to noncarriers of a higher magnitude and 307 significance compared to the pooled analysis of control, MCI and AD (β ± SE = 0.64 ± 0.12; *p=6.17x10 -8 ) 308
when correcting for the covariates outlined above. Of note, TET2 rare variant carriers diagnosed with MCI 309 also demonstrated greater decreases in MMSE changes when compared to non-carriers (β ± SE = -0.47 ± 310 0.17; *p=0.01). Within controls (n=6), there were no significant associations between TET2 variant carrier 311 status and either CDRSB or MMSE. 312 In this study, we identified a significant excess of rare, likely deleterious variation in TET2 as a risk 315 factor for multiple neurodegenerative disorders, including EOAD, LOAD, FTD, and ALS. This finding is 316 important for two main reasons. First, TET2 plays an important role in the conversion of methylation to 5-317 hydroxymethylation, implicating dysfunction in a pathway known to be critical during aging 50 and learning 318 and memory 51 in age-associated diseases like LOAD and FTD. Second, it is striking that the effect sizes in 319 both coding and non-coding variant enrichments were comparable. This point suggests that further 320 investigation of non-coding variation in complex disease genome sequencing studies holds potential for the 321 identification of new contributors to disease. 322 TET2 promotes de-methylation of DNA by catalyzing conversion of methylation to 5-323 hydroxymethylation, and is highly expressed in brain (reviewed in 52 ). Defined methylation changes occur 324 with age in humans ("Horvath's clock", reviewed in 50 ) and there is some evidence for an association 325 between increased "methylation age" and disease (systematically reviewed in 53 ). Taken together, this 326 raises speculation that reduced function or loss of TET2, a critical regulator in methylation processes, may 327 have adverse age-associated effects. Evidence from mouse models further supports this idea. Specifically, 328
promoting the conversion of methylation to 5-hydroxymethylation by either exercise-induced upregulation 329 of TET2 54 or artificial overexpression of TET2 55 improves memory in mice by increasing neurogenesis in 330 the dentate gyrus. Conversely, reducing TET2 in mouse hippocampus leads to reduced neurogenesis and 331 impaired memory 55 , consistent with its role in promoting adult neurogenesis in mice 56 . Finally, reduction of 332 TET2 in mouse primary neurons also reduced cell survival 57 . All of these observations are consistent with 333 detrimental consequences of loss of TET2 function and suggest that neurons may be particularly 334 vulnerable to these effects. Further support for a generally important role of TET enzymes comes from a 335 preprint implicating mono-and bi-allelic loss-of-function of TET3 in childhood diseases 58 (TET3 is more 336 constrained against loss-of-function based on population database estimates 35 , which (along with bi-allelic 337 contributions) could explain the earlier ages observed). In addition to general evidence for the importance 338 of TET2 and other TET enzymes, an intriguing and more specific role for TET2 has also been proposed in 339 a preprint implicating TET2 in microglial response, particularly around amyloid plaques 59 , suggesting that conferring TREM2 variants result in loss-of-function). Finally, the human data we analyzed from ADNI is 343 consistent with deleterious consequences of TET2 rare variants, with our observations supporting a faster 344 rate of both general clinical decline (CDRSB) and cognitive decline (MMSE). 345
The strongest association signal in the discovery cohort was a combined analysis across all EOAD 346 and FTD cases together. While we recognize the drawbacks of a combined analysis across phenotypes, 347
we argue that the benefits outweigh the drawbacks for two critical reasons beyond the increase in sample 348 size: (1) known effects of genetic pleiotropy, and (2) the possibility of identifying shared pathways between 349
diseases. 350
The first reason supporting comparison across EOAD and FTD is that genetic pleiotropy-where a 351 single locus contributes variance to multiple, different phenotypes-may play a role in neurodegenerative 352 disease risk. Our group and others have provided support for this idea through several studies investigating 353 multiple neurodegenerative diseases using GWAS approaches [11] [12] [13] [14] [15] . In addition to common risk variants, 354 there is clear evidence of moderately to highly penetrant rare variation in single genes conferring risk or 355 causality for multiple neurodegenerative diseases. First, rare variants in TREM2 confer risk for both AD 61 356 and FTD 62 . Second, rare variation in multiple established genes such as TBK1 and C9orf72 confer risk or 357 are causative across the ALS-FTD spectrum 63 . Third, moderately penetrant common risk alleles like APOE 358 ε4 are primarily associated with AD, but also associated with risk for Dementia with Lewy Bodies (DLB) 64 , 359 FTD 12 , and age of onset in C9orf72 carriers 65 . Fourth, GBA and SNCA were first identified as risk factors 360 for Parkinson's disease (PD), but also confer risk for DLB 64 . Finally, rare pathogenic variants in MAPT 361 typically cause FTD 66; 67 , but the R406W pathogenic variant has also been associated with an EOAD 362 presentation 68; 69 . Furthermore, common variants near MAPT (tagging the H1 haplotype, associated with 363 higher tau expression 70 ) are associated with AD, PD, FTD, and ALS 11; 12; 15 . 364 A second important reason to analyze across different patient populations is that performing 365 analyses across cohorts of patients diagnosed with different neurodegenerative disorders but with partially 366 overlapping underlying neuropathology (i.e., tau-containing protein aggregates in both AD and 367 approximately half of FTD cases; TDP-43 containing protein aggregates in ALS, approximately half of FTD 368 cases, and some AD cases) may identify shared dysregulated pathways, and has the potential to identify rare variation in TET2 is associated with multiple neurodegenerative diseases suggests age-related 371 changes in methylation may be relevant across a broad spectrum of neurodegeneration. 372
In conclusion, we provide evidence that loss of TET2 function confers risk for EOAD, LOAD, FTD, 373 and ALS. Specifically, we found that, in aggregate, both coding and non-coding qualifying rare variation in 374 TET2 is associated with approximately a 2-fold risk increase across diverse populations of patients with 375 AD, FTD, and ALS, and that canonical loss-of-function variation in TET2 is associated with approximately a 376 3-fold risk increase for these diseases. We note that, similar to any burden test, it is impossible from 377 aggregate enrichment values to deconvolute variable penetrance levels among disease-relevant alleles 378 and the degree of enrichment for truly associated variation. ACKNOWLEDGEMENTS 392 393
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SUPPLEMENTAL

SUPPLEMENTAL TABLES Supplemental
